Economy
Novartis tumbles after third setback in a week
On 2026-09-08, shares of Swiss pharmaceutical company Novartis fell by as much as 10.7% on the Zurich stock exchange. The decline followed news that the potential blockbuster drug del-desiran failed to pass a testing phase. This marks the third setback for Novartis within a week, raising concerns among investors about the company's pipeline. The news was reported by FD, highlighting the significant impact of the failed test on Novartis’s market performance and investor confidence.
Ozetta summarises; the reporting is the newsroom's